Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ascendis Pharma A (ASND) Gross Profit: 2014-2025

Historic Gross Profit for Ascendis Pharma A (ASND) over the last 12 years, with Sep 2025 value amounting to $223.6 million.

  • Ascendis Pharma A's Gross Profit rose 336.65% to $223.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $625.5 million, marking a year-over-year increase of 107.95%. This contributed to the annual value of $345.7 million for FY2024, which is 44.51% up from last year.
  • According to the latest figures from Q3 2025, Ascendis Pharma A's Gross Profit is $223.6 million, which was up 56.04% from $143.3 million recorded in Q2 2025.
  • In the past 5 years, Ascendis Pharma A's Gross Profit ranged from a high of $223.6 million in Q3 2025 and a low of $899,852 during Q1 2021.
  • Its 3-year average for Gross Profit is $94.5 million, with a median of $87.8 million in 2025.
  • Its Gross Profit has fluctuated over the past 5 years, first plummeted by 63.37% in 2021, then spiked by 1,054.34% in 2022.
  • Quarterly analysis of 5 years shows Ascendis Pharma A's Gross Profit stood at $1.6 million in 2021, then surged by 1,054.34% to $18.1 million in 2022, then surged by 601.20% to $127.2 million in 2023, then surged by 34.30% to $170.9 million in 2024, then surged by 336.65% to $223.6 million in 2025.
  • Its Gross Profit stands at $223.6 million for Q3 2025, versus $143.3 million for Q2 2025 and $87.8 million for Q1 2025.